5-Year MMC vs. ologen™ CM Study finds the latter with 37% Higher Success Rates

5-Year MMC vs. ologen™ CM Study finds the latter with 37% Higher Success Rates

 

A new study published in the Journal of Ophthalmology in May finds that using collagen matrix implants (available commercially as ologen™ CM) in place of mitomycin C (MMC) can significantly increase the long-term (5 year) success rates of open-angle glaucoma treatment via trabeculectomy for Chinese patients.

A total of 63 eyes – a significantly high number of test subjects for trabeculectomy studies – received randomized treatments of either trabeculectomy with ologen™ CM or trabeculectomy with MMC. Eye pressure (IOP), eye tissue health, post-operative complications and other indicators were measured, analyzed and tracked regularly for five years, which makes it a milestone – the longest follow-up study on the subject to date.

Trabeculectomy is the current gold standard of glaucoma surgical treatments. Aeon Astron Europe, the manufacturer of ologen™ CM, is encouraged by the extremely positive results of this 5-year study. Large-scale and long-term studies such as this are important additions to an increasing body of evidence that collagen implants with anti-fibrotic functions may outperform anti-metabolite agent MMC in primary open-angle glaucoma treatments.

The company anticipates more research interests to ensue as multiple trabeculectomy-collagen matrix trials worldwide begin conclude in the near future. They are expected to yield the same powerful long-term care results in support of the increasing adoption of the collagen matrix.

Citation: Yuan, F., Li, L., Chen, X., Yan, X., & Wang, L. (n.d.). Biodegradable 3D-Porous Collagen Matrix (ologen™) Compared with Mitomycin C for Treatment of Primary Open-Angle Glaucoma: Results at 5 Years. Journal of Ophthalmology, 2015, 1-7.

Funding: The authors have no proprietary or commercial interest in any materials discussed in this paper.